Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILIT.FT dose-finding trial of intralymphatic grass allergen immunotherapy
2020-005823-35Phase 2Completed
- Sponsor
- Aarhus University
- Start
- Dec 2020
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of alutard phleum pratense in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (3 arms), sponsored by Aarhus University. Primary endpoint: Reduction in median combined symptom and medication score. Started Dec 2020; status: completed.
02
Drugs
alutard phleum pratense
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2020-005823-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005823-35.